Lupin Limited entered into a contract with Medis for Lupin’s orphan drug NaMuscla (mexiletine). Further, for the symptomatic management of people with non-dystrophic myotonic (NDM) diseases, Medis will market NaMuscla in Central and Eastern European nations.
Novartis AG collaborated with Dr. Reddy's Laboratories which is exclusive for certain of its well-known medications, such as the Voveran range, the Calcium range, and Methergine. Further, the agreement aims to increase patient’s access to these medications beyond present geographic boundaries.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4109
Published Date: Aug 08, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Rising geriatric population and the growing incidences of cardiovascular diseases are the major factors driving the market growth
The market size of prils is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023 â€“ 2035.
The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
The major players in the market are Novartis AG, Manus Aktteva Biopharma LLP, Canagen Pharmaceuticals Inc., and Lupin Limited., and others.
The hypertension segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.